大连股交中心目前大股东为大连市国有金融资本管理运营有限公司。"大连股交中心的发展，获得了大 连金运公司及旗下担保、租赁、保理等板块丰富的金融资源支持。"王松说。 值得一提的是，目前，大连股交中心部分高管还在大连市引导基金管理有限责任公司任职。以王松为 例，其另一身份是大连引导基金管理公司总经理。大连引导基金管理公司是由大连金运公司出资设立的 大连市政府引导母基金管理机构，采取市场化、专业化方式管理运营。 大连股交中心总经理王松日前在接受中国证券报记者专访时表示，作为大连市唯一合法的区域性股权市 场运营机构，大连股交中心将坚持高标准站位，保持韧性、耐心和定力，以沉下去的功夫做好各项基础 工作，发挥多层次资本市场"塔基"和企业上市"苗圃"作用，扩大特色优势，为优质中小企业提供全方 位、全生命周期的金融服务，聚焦专精特新企业梯度培育，打通资本与实体经济连接通道，助力优质企 业利用资本市场实现高质量发展。 成果丰硕 近日，大连股交中心"专精特新"专板培育层企业康丰科技获准挂牌新三板。这家深耕连续挤压和包覆技 术领域的科技型企业曾三次荣获国家科技进步奖，此次能快速在新三板挂牌、实现在资本市场进阶发 展，正是得益于三四板 ...

大连股交中心总经理王松日前在接受中国证券报记者专访时表示，作为大连市唯一合法的区域性股权市 场运营机构，大连股交中心将坚持高标准站位，保持韧性、耐心和定力，以沉下去的功夫做好各项基础 工作，发挥多层次资本市场"塔基"和企业上市"苗圃"作用，扩大特色优势，为优质中小企业提供全方 位、全生命周期的金融服务，聚焦专精特新企业梯度培育，打通资本与实体经济连接通道，助力优质企 业利用资本市场实现高质量发展。 特色优势显著 大连股交中心目前大股东为大连市国有金融资本管理运营有限公司。"大连股交中心的发展，获得了大 连金运公司及旗下担保、租赁、保理等板块丰富的金融资源支持。"王松说。 值得一提的是，目前，大连股交中心部分高管还在大连市引导基金管理有限责任公司任职。以王松为 例，其另一身份是大连引导基金管理公司总经理。大连引导基金管理公司是由大连金运公司出资设立的 大连市政府引导母基金管理机构，采取市场化、专业化方式管理运营。 在挖掘及走访企业过程中，大连股交中心与大连引导基金管理公司两家兄弟单位往往共同参与，实现资 源共享、优势互补，进一步提升走访实效，找出一批好企业并实现长期赋能。 "大连股交中心与大连引导基金管理公司协 ...

● 本报记者 宋维东 大连股交中心总经理王松日前在接受中国证券报记者专访时表示，作为大连市唯一合法的区域性股权市 场运营机构，大连股交中心将坚持高标准站位，保持韧性、耐心和定力，以沉下去的功夫做好各项基础 工作，发挥多层次资本市场"塔基"和企业上市"苗圃"作用，扩大特色优势，为优质中小企业提供全方 位、全生命周期的金融服务，聚焦专精特新企业梯度培育，打通资本与实体经济连接通道，助力优质企 业利用资本市场实现高质量发展。 成果丰硕 近日，大连股交中心"专精特新"专板培育层企业康丰科技获准挂牌新三板。这家深耕连续挤压和包覆技 术领域的科技型企业曾三次荣获国家科技进步奖，此次能快速在新三板挂牌、实现在资本市场进阶发 展，正是得益于三四板"绿色通道"机制的全程协助。 "为破解企业挂牌周期长、流程衔接难等痛点，2024年大连股交中心与全国股转公司签署《监管合作备 忘录》，正式开通三四板'绿色通道'，为以专精特新企业为代表的拟挂牌、拟上市企业搭建对接资本市 场的直达通道。"王松说。 康丰科技的快速挂牌，正是大连股交中心高效链接全国性资本市场资源、助力区域优质企业加速对接新 三板的有益实践，也是精准服务中小企业的经典案例。 ...

关于货币资金及存货核查情况。公司表示，货币资金变动与营业收入、应收应付项目变动、投融资情况 具有匹配性；报告期内，测算的平均存款利率整体上处于利率的合理区间范围内，各期利息收入与银行 存款规模相匹配，银行存款与利息收入的勾稽关系不存在异常。2025 年 1-6 月销量、销售价格下降的 主要产品处于正常销售状态，备货比例适当，并按企业会计准则的要求计提存货跌价准备；发行人生产 不依赖于专用生产设备，主要生产设备为通用设备；报告期各期末发行人对固定资产进行盘点，相关生 产设备未发生闲置情形，无减值迹象。 关于其他问题，公司也一一进行了回复。 同壁财经了解到，公司是一家主要从事汽车传动及动力系统精密零部件研发、生产和销售的高新技术企 业，秉承"质量是企业生存的根、创新是企业发展的路"的经营理念，致力于成为汽车精密零部件领域领 先的高质量制造服务商。 安徽省小小科技股份有限公司于12月15日在北交所更新上市申请审核动态，该公司已回复第二轮审核问 询函，回复的问题主要有，关于经营业绩稳定性，关于收入真实性核查，关于货币资金及存货核查情况 等。 关于经营业绩稳定性。公司表示，当前业绩波动系行业转型期与企业自身结构性调整共 ...

Core Viewpoint - Antai Technology (000969.SZ) is enhancing its competitive position in the welding materials sector through strategic investment and structural adjustments during the 14th Five-Year Plan period [1] Group 1: Company Performance and Strategy - Antai San Ying is focusing on market demand to continuously adjust its industrial structure and upgrade its products, leading to steady improvement in operational performance [1] - The company has been recognized as a "specialized, refined, distinctive, and innovative" small and medium-sized enterprise in Tianjin, as well as a "Cheetah Enterprise" [1] Group 2: Investment and Ownership Changes - The company plans to invest an additional 20 million RMB in Antai San Ying using its own funds, with 17,915,330 RMB allocated to registered capital and the remainder to capital reserves [1] - Following this capital increase, the company's ownership stake in Antai San Ying will rise from 50.588% to 59.1898%, maintaining Antai San Ying as a controlled subsidiary whose financial statements will continue to be included in the company's consolidated financial statements [1]

Core Viewpoint - Haosen Pharmaceutical has been recognized as a national-level "specialized, refined, and innovative" small giant enterprise, which enhances its brand recognition and industry influence, positively impacting its overall development [1][2]. Group 1: Recognition and Impact - The company was previously recognized as a specialized and innovative small enterprise in Zhejiang Province in 2021 and has now achieved national-level recognition [1]. - This recognition by the Ministry of Industry and Information Technology acknowledges the company's technological level, innovation capability, manufacturing quality, and overall strength [1]. Group 2: Research and Development - In the first three quarters of 2025, the company invested a total of 28.1661 million yuan in research and development, representing a year-on-year increase of 57.96% [1]. - The company is pursuing a multi-channel and diversified approach to convert research outcomes into market value through collaborations with research enterprises and universities [1]. Group 3: Product Pipeline - As of June 30, 2025, the company has 17 products under research, including APIs, intermediates, and formulations, targeting various therapeutic areas such as antiviral, antidepressant, lipid-lowering, non-steroidal anti-inflammatory, anti-rheumatic, and anti-ulcer medications [1]. Group 4: Corporate Mission and Strategy - The company is committed to continuously researching, producing, and promoting excellent pharmaceutical products and services to enhance people's quality of life [2]. - It focuses on the research, production, and sales of chemical pharmaceutical raw materials, intermediates, and formulations, aiming for specialized development and increased R&D investment to strengthen its core competitiveness [2].

格隆汇12月15日丨海森药业(001367.SZ)公布，根据国家工业和信息化部发布的《工业和信息化部关于 公布第七批专精特新"小巨人"企业和2025年通过复核专精特新"小巨人"企业名单的通告》，浙江海森药 业股份有限公司通过第七批专精特新"小巨人"企业认定。 股票频道更多独家策划、专家专栏，免费查阅>> 责任编辑：山上 ...

每经AI快讯，海森药业（SZ 001367，收盘价：21.73元）12月15日晚间发布公告称，根据国家工业和信 息化部发布的《工业和信息化部关于公布第七批专精特新"小巨人"企业和2025年通过复核专精特新"小 巨人"企业名单的通告》，浙江海森药业股份有限公司（简称"公司"）通过第七批专精特新"小巨人"企 业认定。 公司继被认定为2021年浙江省专精特新中小企业后，本次被认定为国家级专精特新"小巨人"企业，是国 家工业和信息化部对公司技术水平、创新能力、生产制造水平及综合实力等多方面的认可，有利于提高 公司的品牌知名度和在行业内的影响力，对公司整体发展产生积极影响。 2025年1至6月份，海森药业的营业收入构成为：医药制造业占比100.0%。 截至发稿，海森药业市值为33亿元。 每经头条（nbdtoutiao）——"一针两千，童颜针年销3亿元"背后：多家关联方注册地"查无此人"，股民 追问"钱呢"！钱氏姐弟几乎"掏空"江苏吴中，公司即将退市 （记者 王晓波） ...

Group 1 - Shenzhen leads China with a total of 1,333 "specialized, refined, distinctive, and innovative" (专精特新) "little giant" enterprises, surpassing Beijing (1,210) and Shanghai (1,032) [2][3] - The growth of "little giant" enterprises in Shenzhen reflects a focus on key segments of the industrial chain, mastery of core technologies, and high market share, indicating a high level of development in China's manufacturing sector [3] - Shenzhen's proportion of newly added "little giants" has increased from 6.3% in 2022 to 8.4% in 2023, and is projected to reach 9.8% in 2024 and 9.9% in 2025, maintaining the top position in the country for three consecutive years [4] Group 2 - Notable "little giants" include Jieput's MOPA pulsed fiber laser, which holds over 70% of the domestic market and ranks first globally, and Guangyue Technology, which has developed world-leading high-power transmission cable series [4] - Shenzhen's "little giants" exhibit an average R&D intensity of 7.63%, with annual R&D expenditure averaging 33.39 million yuan, surpassing the national average for similar enterprises [4] - The city has established a comprehensive nurturing system for enterprises, with plans to support "gazelle" and "unicorn" companies through a structured service system aimed at fostering innovation and collaboration within the electronic manufacturing ecosystem [5]

Core Viewpoint - Wuzhou Medical has seen a 4.44% increase in stock price, with a trading volume of 151 million yuan and a market capitalization of 3.085 billion yuan, indicating positive market sentiment towards the company [1] Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, including various types of syringes, infusion sets, blood transfusion devices, and other related medical supplies [2] - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong market position and innovation capabilities [2] - As of October 20, the company reported a revenue of 345 million yuan for the first nine months of 2025, reflecting a year-on-year growth of 0.82%, while the net profit attributable to shareholders decreased by 46.09% to 18.51 million yuan [7] Group 2: Financial Performance - The company’s overseas revenue accounts for 96.88% of total revenue, benefiting from the depreciation of the Chinese yuan [3] - The average trading cost of the stock is 42.55 yuan, with the current stock price fluctuating between resistance at 47.98 yuan and support at 43.15 yuan, suggesting potential for short-term trading strategies [6] - Wuzhou Medical has distributed a total of 81.6 million yuan in dividends since its A-share listing [8] Group 3: Market Activity - The stock has experienced a net inflow of 3.86 million yuan from major investors today, with a total of 95.76 million yuan net inflow in the industry over the past two days [4][5] - The stock's trading volume indicates a dispersed distribution of shares among major investors, with major transactions accounting for 7.61% of total trading volume [5]